Giulia
@GiuliaOrlandoGO
Epigenetic reprogramming, single-cell, gene regulation, cancer biologist. Starting my lab in Sep 2025 at @OxfordOncology. Mom of 2.
Exciting news!!! We are recruiting a RA to join my lab at @OxfordOncology in September to study epigenetic reprogramming in stem cells and within the TME using colon organoids oncology.ox.ac.uk/team/giulia-or… Deadline 2nd of July (my.corehr.com/pls/uoxrecruit…) Re-post are very welcome!
We’re investing £600,000 into four groundbreaking research projects, each aimed at developing kinder, more effective treatments for various aggressive blood cancers. 🧡 Meet the talented female researchers being awarded a John Goldman Fellowship: leukaemiauk.org.uk/news/leukaemia…
Thank you @LeukUK for the support in developing this project !
Dr Giulia Orlando @GiuliaOrlandoGO, from @UniofOxford, has been studying RAS pathways in the gene network of juvenile myelomonocytic leukaemia (JMML) 🧬
I’ve had a hysteroscopy and HSG without anaesthetic (general or local) and it was the most painful thing I have ever experienced. The second procedure went on for 40 minutes, I cried the whole way through. Well done to the women here who have spoken out. bbc.com/news/articles/…
First pre-print from the lab! Together with @lucapinello and @danielevanbauer we developed CRISPR-CLEAR, an experimental and computational pipeline to dissect enhancers at nucleotide resolution. biorxiv.org/content/10.110…
We're recruiting a postdoc to join my lab at @OxfordOncology & Centre for Immuno-Oncology, @UniofOxford to understand immune regulation in cancer and develop new approaches for cancer prevention and metastasis. Deadline: 11 August 2025 Apply here: my.corehr.com/pls/uoxrecruit…
1/2 The interview series "Reprogramming Stars" featured in Cellular Reprogramming, highlights the work of leaders in the field by introducing them and their science in exciting talks. @CellRepJrnl
What's heritable and what's plastic in cancer drug resistance? The two are linked! (Epi)genetic molecular memory is under Darwinian selection but encodes multiple plastic phenotypes. We found this with organoid experimental evolution + ML for multiomics. aacrjournals.org/cancerres/arti…
NEW: Oxford University researchers have uncovered a potential new therapeutic target in a particularly aggressive and hard-to-treat form of leukaemia. Read more ⬇️
🚨🚨Paper out! 🚨🚨 Delighted to share our work, now published in @NatureGenet 🧬! shorturl.at/94s5S We identified a targetable, chromothripsis-associated genetic event in blast phase (BP) MPN, a particularly poor prognostic subtype of acute leukaemia. 1/n 🧵👇
Would you prefer to lead a lab alone or together with a science buddy? How interesting would be a research institute where joint labs are the standard?!
What is the most common type of mutations, causing cancer and genetic diseases? C to T mutations in CpGs: Signature 1. What is the best understood mutational signature? Signature 1. Or is it? Results of over 8 years of our work is finally out! 🧵1/ nature.com/articles/s4158…
Thrilled to see this work out @ScienceTM dissecting how MPN cancer cells reprogram their niche to fuel progression, and uncovering Galectin-1 as a targetable mediator science.org/doi/10.1126/sc…
NEW: Research from the @beth_psaila, @AdamMead_Oxford and @gabyrabi labs has identified galectin-1 as a new biomarker and therapeutic target for blood cancers. Published yesterday in @ScienceTM 🎉 Read the full story here: imm.ox.ac.uk/news/galectin-… @MRC_WIMM | @RDMOxford |…
biorxiv.org/content/10.110… Check out our latest pre-print! We identify how dysregulated C5aR1 signalling contributes to tumour cell survival in the hypoxic tumour microenvironment and provide new insights into the most effective pharmacological targeting of the C5a/C5aR1 axis
Our pan-KRAS PROTAC degrader ACBI3 is now live and available to order on @Boehringer #OpnMe portal. Thanks to the team for making this available to scientists for free so quickly after the release of our @ScienceMagazine publication! opnme.com/molecules/pan-…
We plan to make ACBI-3 freely available for the community through the #OpnMe portal, no strings attached. We welcome feedback on this study, and hope ACBI-3 will prove invaluable in accelerating further research on this important cancer target. 6/8 opnme.com
PATH (phylogenetic analysis of trait heritability) is out @NatureGenet! Excited about tackling the fundamentals of somatic evolution: *measuring cell state heritability *a quantitative definition for cell plasticity (1-heritability) *cell-state transition dynamics 👀🧵👇
Excited to share "Defining heritability, plasticity, and transition dynamics of cellular phenotypes in somatic evolution", from an amazing collaboration with @landau_lab @ar_davino @TamaraPrietoF @hara_toshiro @MarioSuva! A tweetorial, or Xplanation ... nature.com/articles/s4158…
What a wonderful event @LeukUK! It was an honour to be invited and sharing the evening with @CKBrierley @h_peckham and @Dr_Valletta! Thank you for the support to myself and other leukaemia scientists!
We’ve officially raised OVER £8 MILLION in the 25 years of Who’s Cooking Dinner!! 🎉 Last night, you helped us raise over £280,000 for life-saving leukaemia research, which means we’ve now surpassed the £8 million mark since this incredible event began! (1/2)
Thrilled to share that, together with my colleagues @UoDCeTPD and collaborators @Boehringer, we report @ScienceMagazine the breakthrough discovery and characterization of a small-molecule that degrades most oncogenic mutant forms of KRAS. 1/8 science.org/doi/10.1126/sc…
Super thrilled to share our article on pharmacological PU.1 repositioning published in Nature Genetics today! Massive thanks to everyone involved! Article -> nature.com/articles/s4158… A digestible PUree of the main findings (aka Research Brief) -> nature.com/articles/s4158…
We are pleased to present our latest publication in @NatureGenet investigating the functional basis behind the #genetic risk variants in #colorectalcancer (CRC) nature.com/articles/s4158… #cancer #bowelcancer 🧵 1/